Detalles de la búsqueda
1.
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Oncologist;
26(12): 1026-1034, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34355457
2.
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
BJU Int;
128(5): 607-614, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909949
3.
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
J Urol;
204(6): 1173-1179, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32552295
4.
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.
Oncologist;
24(10): 1348-1355, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30936379
5.
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
J Urol;
200(6): 1207-1214, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30012366
6.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Acta Oncol;
57(4): 491-497, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28853615
7.
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
J Urol;
191(4): 898-906, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24300483
8.
Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011.
Eur Urol Focus;
8(3): 646-647, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35450799
9.
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.
Mol Cancer Ther;
21(11): 1674-1688, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35999659
10.
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.
Urol Oncol;
38(12): 934.e1-934.e9, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32660788
11.
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Eur Urol Focus;
5(2): 242-249, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28753897
12.
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Cancer Med;
6(1): 186-194, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28000388
13.
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
Clin Genitourin Cancer;
2017 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28923700
14.
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy.
Urol Oncol;
34(6): 256.e15-21, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26944451
15.
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Eur Urol;
69(4): 634-641, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26264159
16.
Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
Clin Genitourin Cancer;
14(4): 331-40, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26589729
17.
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Bladder Cancer;
2(4): 405-413, 2016 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28035321
18.
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Clin Genitourin Cancer;
13(2): 178-84, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25450035
19.
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Clin Genitourin Cancer;
13(2): 185-92, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25458370
20.
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Clin Genitourin Cancer;
12(2): 130-7, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24220220